Search Results
Your search for all items matches 34944 pages
Showing 3601 - 3650CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Overall Survival With Axicabtagene Ciloleucel in Large B-Cell Lymphoma: Results From ZUMA-7
As reported in The New England Journal of Medicine by Jason R. Westin, MD, and colleagues, the overall survival analysis from the phase III ZUMA-7 trial showed significant benefit with axicabtagene ciloleucel vs standard care in patients with early relapsed or refractory large B-cell lymphoma. The...
Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Faron et al found that neoadjuvant chemotherapy and chemoradiotherapy were associated with better survival vs upfront surgery in patients with thoracic esophageal or gastroesophageal junction (GEJ) carcinoma. Study Details The study...
FDA Approves Quizartinib for Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
On July 20, the U.S. Food and Drug Administration (FDA) approved quizartinib (Vanflyta) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adults with newly diagnosed acute...
Expert Point of View: Nabil F. Saba, MD, FACP, and Jennifer Choe, MD, PhD
Nabil F. Saba, MD, FACP, Professor and Vice Chair of Hematology and Medical Oncology, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, and Director of the HNCA Medical Oncology Program at the Winship Cancer Institute, Emory University, Atlanta, was invited to discuss the...
JUPITER-02: Toripalimab Plus Chemotherapy Improved Survival Outcomes for Some Patients With Advanced Nasopharyngeal Carcinoma
In the final overall survival analysis of the phase III JUPITER-02 trial, first-line treatment with toripalimab plus gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs chemotherapy alone in...
Psilocybin and Other Psychedelics May Help Patients With Late-Stage Gynecologic Cancer Tackle Mental Health Symptoms
Investigators revealed that psilocybin-assisted psychotherapy and other psychedelics may effectively ease symptoms of anxiety and depression in patients with late-stage gynecologic cancers, according to a new commentary published by Yaniv et al in the International Journal of Gynecological Cancer. ...
Biological Aging and Radiation Therapy for Breast Cancer
Some patients who have received treatment for breast cancer may experience increased biological aging compared with those who have never been diagnosed with breast cancer, according to a new study published by Kresovich et al in the Journal of the National Cancer Institute. The findings showed that ...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
Implementation of Pediatric Early Warning Systems in Resource-Limited Latin American Hospitals
In a study reported in The Lancet Oncology, Agulnik et al found that implementation of pediatric early warning systems resulted in reduced clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America. Study Details The Proyecto Escala de...
Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Current Management of and Future Possibilities for Triple-Negative Breast Cancer
“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...
Incorporation of Gilteritinib Into Induction and Consolidation Chemotherapy and as Maintenance Therapy in Newly Diagnosed Patients With AML
In a phase Ib trial (2215-CL-0103) reported in the Journal of Clinical Oncology, Keith W. Pratz, MD, and colleagues found that incorporation of the FLT3 inhibitor gilteritinib into intensive induction and consolidation chemotherapy and its use as single-agent maintenance therapy were associated...
Activity and Toxicity of Pembrolizumab in Rare Sarcomas
In a French phase II basket trial (AcSé Pembrolizumab) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues investigated the activity and safety of pembrolizumab in patients with rare sarcomas. AcSé Pembrolizumab is an ongoing phase II multitumor study investigating the activity of...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
Turning Fear Into Hope
The first sign that pancreatic cancer was stalking my family was in 1982, when my mother was diagnosed with stage IV disease. She was just 54 years old and died several months later. After two more family members in their early 50s were also diagnosed with the cancer, I began to worry that I would...
Investigators Offer Guidance for Improving Access to Oncology Drugs in Sub-Saharan Africa
Investigators have addressed the need to improve access to oncology drugs designed to increase the survival and quality of life of patients in sub-Saharan Africa and combat the significant health-care disparities many of these patients continue to face, according to a new study published by Sharma...
Diversity May Play a Key Role in Black Patients’ Trust of Videos About Prostate Cancer
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
SSO Names Chandrakanth Are, MBBS, MBA, Chief Executive Officer of Global Forum of Cancer Surgeons
As a member of the Global Forum of Cancer Surgeons, the Society of Surgical Oncology (SSO) is pleased to announce that Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, has been named Chief Executive Officer of the Global Forum of Cancer Surgeons. Dr. Are holds the title of Jerald L. and Carolynn J....
ASCO Remembers Former Board of Directors Member and Radiation Oncologist A. William Blackstock, Jr, MD, FASCO
ASCO is deeply saddened by the death of A. William Blackstock, Jr, MD, FASCO, who served on the Society’s Board of Directors from 2018 to 2022. Dr. Blackstock passed away on June 18, 2023, from complications of prostate cancer. He was 60 years old. “We mourn the passing of a friend and colleague...
Study of Cancer Metastasis Receives $35 Million Boost at Johns Hopkins Medicine
With a $35 million gift from researcher, philanthropist, and race car driver Theodore Giovanis, FHFMA, MBA, scientists at Johns Hopkins Medicine will study the biologic roots of the most fatal aspect of cancer: how it metastasizes through the body. The contribution, which is a 15-year commitment,...
Damon Runyon Names Physician-Scientist Awardees
Three scientists who are researching novel approaches to the treatment of cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award: Nicole M. Cruz, MD; Mounica Vallurupalli, MD; and Nina Weichert-Leahey, MD. The awardees were selected through a highly...
Berberine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the use of...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Allison Institute Announces Appointment of Inaugural Members
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center has announced the appointment of its first members, including pioneering researchers who have made notable contributions to science as well as rising stars on the path toward important breakthroughs. This group will ...
Expert Point of View: Gustavo Werutsky, MD and Lisa A. Carey, MD, ScM, FASCO
Invited discussant Gustavo Werutsky, MD, emphasized that health-related quality of life was consistently maintained in all phase III trials with fam-trastuzumab deruxtecan-nxki (T-DXd) in the metastatic breast cancer setting. Dr. Werutsky also highlighted the need for real-world data to understand...
Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer
Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...
Expert Point of View: Kathleen Moore, MD, MS
“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...
In Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study Among Patients With BRCA Mutation
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Study Examines Impact of Modified Treatment Protocols on Survival in Pediatric Patients With ALL
The 5-year survival rate of pediatric patients with acute lymphoblastic leukemia (ALL) has continued to increase to 94%, according to a new study published by Pieters et al in the Journal of Clinical Oncology. Background ALL is the most common form of pediatric cancer in the Netherlands—with about...
Neoadjuvant and Adjuvant GVAX Plus Nivolumab and Urelemab May Increase Immune Response in Patients With Resectable Pancreatic Cancer
A combination of the pancreatic cancer vaccine GVAX, the immune checkpoint inhibitor nivolumab, and the anti-CD137 agonist antibody urelemab may be safe and increase the amount of immune T cells in the tumors of patients with operable pancreatic cancer when given 2 weeks prior to surgical tumor...
Expert Point of View: Barbara Burtness, MD
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Trends in Receipt of End-of-Life Systemic Treatment for Patients With Cancer
In a U.S. study reported in the Journal of Clinical Oncology, Canavan et al found that White vs Black patients, patients with commercial insurance vs Medicare/Medicaid, and patients treated at community practices vs academic centers were more likely to receive end-of-life systemic therapy for...
Adjuvant Nivolumab vs Observation for Patients With Completely Resected Merkel Cell Carcinoma
As reported in The Lancet by Becker et al, an interim analysis of a European phase II study (ADMEC-O) showed that adjuvant nivolumab was associated with a numeric benefit in disease-free survival vs observation in patients with completely resected Merkel cell carcinoma. Study Details In the...
First-Line Pembrolizumab/Lenvatinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In the phase II KEYNOTE-B61 trial reported in The Lancet Oncology, Laurence Albiges, MD, PhD, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal cell carcinoma. As stated by the investigators,...
Regional Nodal Irradiation and Locoregional Recurrence in Patients With Favorable-Risk Node-Positive Breast Cancer
In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional nodal irradiation in patients with favorable-risk, node-positive breast cancer receiving radiation...
Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas
In a small phase II trial reported in The New England Journal of Medicine, Priscilla K. Brastianos, MD, and colleagues found that the BRAF-MEK inhibitor combination of vemurafenib and cobimetinib produced an objective response in almost all patients with newly diagnosed papillary craniopharyngiomas ...
Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition
In the phase III CONTACT-03 trial reported in The Lancet, Sumanta Pal, MD, FASCO, and colleagues found that the addition of atezolizumab to cabozantinib did not improve outcomes in patients with renal cell carcinoma whose disease progressed on or after prior immune checkpoint inhibitor treatment....
Lazertinib vs Gefitinib in the First-Line Treatment of EGFR-Mutated Advanced NSCLC
In a phase III trial (LASER301) reported in the Journal of Clinical Oncology, Byoung Chul Cho, MD, PhD, and colleagues found that lazertinib improved progression-free survival vs gefitinib in the first-line treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC). As stated by the...
Cetuximab Plus Radiotherapy Shows Activity in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma
Investigators have discovered that cetuximab in addition to concurrent radiotherapy may be safe and effective at treating patients with locally advanced cutaneous squamous cell carcinoma, according to a recent study published by Chang et al in Oncotarget. Treatment for locally advanced cutaneous...
APOBEC3A Protein May Be Linked to Drug Resistance in Patients With NSCLC
Researchers have uncovered how non–small cell lung cancer (NSCLC) tumors may develop drug resistance over time and identified the APOBEC3A protein as a potential target for novel cancer therapeutics, according to a study published by Isozaki et al in Nature. The findings point to potential...
Aspartame Hazard and Risk Assessment Results Released by IARC and JECFA
Assessments of the health impacts of the nonsugar sweetener aspartame were released today by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO)/Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Citing “limited...
Crenigacestat Plus BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In a single-institution, phase I, first-in-human trial reported in The Lancet Oncology, Cowan et al found that the combination of the γ-secretase inhibitor (GSI) crenigacestat and B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was tolerable and produced a high...
Meta-analysis of the Addition of Docetaxel to ADT in Metastatic Hormone-Sensitive Prostate Cancer
In a systematic review and individual patient meta-analysis reported in The Lancet Oncology, Claire L. Vale, PhD, and colleagues in the STOPCAP M1 collaboration identified factors associated and not associated with improved outcomes after the addition of docetaxel to androgen-deprivation therapy...
